5-MTHF reduces the potential for masking the haematological symptoms of vitamin B12 deficiency, and
5-MTHF may be associated with a reduced interaction between drugs that inhibit dihydrofolate reductase.
Overall conclusions which have been drawn are that “the two compounds have comparable physiological activity, bioavailability and absorption at equimolar doses...” and that “5-MTHF is at least as effective as folic acid in improving folate status, as measured by blood concentrations of folate and by functional indicators of folate status, such as plasma homocysteine.”
However, there is an exception to the above conclusions. Recent studies have uncovered that approximately half the European population appear to have a mutation in the methylenetetrahydrofolate reductase gene, which leads to inactivation, or impaired function of the methylenetetrahydrofolate reductase (MTHFR) enzyme.
The MTHFR enzyme is responsible for the formation of 5-MTHF. Therefore a mutation in this gene can result in moderately elevated levels of homocysteine in the blood, among other problems, and for women there is an increased risk of having a miscarriage or a baby with neural tube defects. Supplementation with 5-MTHF over folic acid in these situations gives you the opportunity to deliver the reduced (activated) folate that does not need to be converted by the reductase enzyme. Furthermore, it avoids the build up of free folic acid in the circulation.
Magnafolate® ,the Manufacturers & Supplier of L-5-Methylfolate.

Español
Português
русский
Français
日本語
Deutsch
tiếng Việt
Italiano
Nederlands
ภาษาไทย
Polski
한국어
Svenska
magyar
Malay
বাংলা ভাষার
Dansk
Suomi
हिन्दी
Pilipino
Türkçe
Gaeilge
العربية
Indonesia
Norsk
تمل
český
ελληνικά
український
Javanese
فارسی
தமிழ்
తెలుగు
नेपाली
Burmese
български
ລາວ
Latine
Қазақша
Euskal
Azərbaycan
Slovenský jazyk
Македонски
Lietuvos
Eesti Keel
Română
Slovenski
मराठी
Srpski језик 








Online Service